Dronedaron
Dronedaron je organsko jedinjenje, koje sadrži 31 atom ugljenika i ima molekulsku masu od 556,756 Da.[1][2][3][4][5][6][7]
Klinički podaci | |
---|---|
Drugs.com | Monografija |
Način primene | Oralno |
Farmakokinetički podaci | |
Poluvreme eliminacije | 13-19 h |
Izlučivanje | Renalno |
Identifikatori | |
CAS broj | 141626-36-0 |
ATC kod | C01BD07 (WHO) |
PubChem | CID 208898 |
DrugBank | DB04855 |
ChemSpider | 180996 |
ChEBI | CHEBI:50659 |
ChEMBL | CHEMBL184412 |
Hemijski podaci | |
Formula | C31H44N2O5S |
Molarna masa | 556,756 |
| |
|
Osobine
уредиOsobina | Vrednost |
---|---|
Broj akceptora vodonika | 5 |
Broj donora vodonika | 1 |
Broj rotacionih veza | 18 |
Particioni koeficijent[8] (ALogP) | 7,0 |
Rastvorljivost[9] (logS, log(mol/L)) | -9,7 |
Polarna površina[10] (PSA, Å2) | 97,2 |
Reference
уреди- ^ Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. PMID 17389667
- ^ Iwamoto T, Watanabe Y, Kita S, Blaustein MP: Na+/Ca2+ exchange inhibitors: a new class of calcium regulators. Cardiovasc Hematol Disord Drug _targets. 2007 Sep;7(3):188-98. PMID 17896959
- ^ Celestino D, Medei E, Moro S, Elizari MV, Sicouri S: Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study. J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):248-57. PMID 17875953
- ^ Pamukcu B, Lip GY: Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. Expert Opin Pharmacother. 2011 Jan;12(1):131-40. doi: 10.1517/14656566.2011.540800. Epub 2010 Dec 2. PMID 21126199
- ^ De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. PMID 22971242
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug _targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
уреди- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
уреди
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |